(Q38292772)

English

Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

author name string

Chris D Nicholls

1

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Kevin G McLure

2

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Michael A Shields

3

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Patrick W K Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

language of work or name

0 references

publication date

22 January 2002

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Journal of Biological Chemistry

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

277

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

12937-12945

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

p53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

p53 and the Li-Fraumeni syndrome

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Definition of a consensus binding site for p53

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

How p53 binds DNA as a tetramer

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Mutation and cancer: statistical study of retinoblastoma

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Mutations in the p53 gene occur in diverse human tumour types

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Mechanisms of p53 loss in human sarcomas

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

p53 mutants without a functional tetramerisation domain are not oncogenic

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

In vitro analysis of the dominant negative effect of p53 mutants

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Solution structure of the tetrameric minimum transforming domain of p53

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

p53 DNA binding can be modulated by factors that alter the conformational equilibrium

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Form of human p53 protein during nuclear transport in Xenopus laevis embryos

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

High-resolution structure of the oligomerization domain of p53 by multidimensional NMR

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Refined solution structure of the oligomerization domain of the tumour suppressor p53

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

An intact HDM2 RING-finger domain is required for nuclear exclusion of p53.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

The MDM2 RING-finger domain is required to promote p53 nuclear export

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

SUMO-1 modification activates the transcriptional response of p53

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

WAF1, a potential mediator of p53 tumor suppression

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

14-3-3sigma is a p53-regulated inhibitor of G2/M progression

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Induction of the growth inhibitor IGF-binding protein 3 by p53

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

A functional p53-responsive intronic promoter is contained within the human mdm2 gene

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Tumor suppressor p53 is a direct transcriptional activator of the human bax gene

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li – Fraumeni patients carrying a mutation to the TP53 gene

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Identifiers

10.1074/JBC.M108815200

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38292772&oldid=1752364847"